多发性骨髓瘤患者血清中LncRNA PRAL的表达及与临床病理参数和预后的关系

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (916 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the expression of long-chain non-coding RNA (LncRNA) PRAL in patients with multiple myeloma (MM) and its relationship with clinicopathological parameters and prognosis. Methods The clinical data of 82 patients with MM diagnosed and treated in the Second Affiliated Hospital of Nantong University (hereinafter referred to as “our hospital”) from January 2016 to January 2017 were selected as case group, 50 patients with other blood diseases in the same period in our hospital were selected as case control group, and 51 persons with physical examination in the same period in our hospital were taken as healthy control group. Quantitative real-time PCR was used to detect the expression of serum LncRNA PRAL of each group, and the expression difference of each group and their relationship with clinicopathological characteristics were statistically analyzed. According to the mean value of serum LncRNA PRAL expression of 2.125, 82 MM patients were divided into high LncRNA PRAL expression group (40 cases) and low LncRNA PRAL expression group (42 cases), the curative effect of the two groups was compared. The prognostic differences in patients with different LncRNA PRAL expression levels were analyzed by Kaplan-Meier survival analysis (Log-rank test). Results The expression of LncRNA PRAL in the case group was significantly lower than the case control group and the healthy control group (P ＜ 0.05). The expression of serum LncRNA PRAL of MM patients with high International staging system (ISS) stage was significantly lower than that in MM patients with low ISS stage (P ＜ 0.05), while the relative expression of serum LncRNA PRAL of patients with different age, gender, diagnostic typing, Durie-Salmon stage, blood lactate dehydrogenase, blood calcium and hemoglobin levels were not statistically significant (all P ＞ 0.05). The curative effect of patients with high expression of LncRNA PRAL was better than that of patients with low expression of LncRNA PRAL (P < 0.05). The 3-year overall survival rate of low LncRNA PRAL expression group was significantly lower than high LncRNA PRAL expression group, and the average survival time was significantly shorter than high LncRNA PRAL expression group(P ＜ 0.05). Conclusion The expression of serum LncRNA PRAL of MM patients is reduced. The low expression of serum LncRNA PRAL is related to the higher ISS stage and the poor prognosis of patients, and may become an important indicator for evaluating the prognosis of MM.

Key words： Multiple myeloma Long-chain non-coding RNA PRAL Clinicopathological characteristics Prognosis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Liyu GU Zheyun ZHOU Xiaodan WANG Ling TAO Jian

Cite this article:

ZHANG Liyu GU Zheyun ZHOU Xiaodan WANG Ling TAO Jian. Expression of LncRNA PRAL in serum of patients with multiple myeloma and its relationship with clinicopathological parameters and prognosis[J]. 中国医药导报, 2020, 17(34): 39-42,47.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I34/39

[1] 宋丽婷，王芳，赵云，等.多发性骨髓瘤及其所在微环境的研究[J].临床合理用药杂志，2018，11（5）：179-180.
[2] 林薇，梁月雄，莫淑宜.化疗序贯CIK细胞输入对老年多发性骨髓瘤患者免疫、炎症因子的影响[J].中国医师杂志，2020，22（2）：275-277.
[3] 李强.多发性骨髓瘤骨病发生机制研究进展[J].医学综述，2016，22（9）：1697-1700.
[4] Wang H，Wang J，Liang CF，et al. Expression of Long Non-Coding RNA PRAL as a Potential Biomarker for Diagnosis in Non-Small-Cell Lung Cancer Patients is Associated with the Inhibition of Cell Proliferation and Metastasis [J]. Clin Lab，2018，64（9）：1341-1348.
[5] Zhou CC，Yang F，Yuan SX，et al. Systemic genome screening identifies the outcome associated focal loss of long noncoding RNA PRAL in hepatocellular carcinoma [J]. Hepatology，2016，63（3）：850-863.
[6] 温一阳，白冰，胡晓舒.长链非编码RNA PRAL在多发性骨髓瘤患者中的表达及其临床意义[J].中国实验血液学杂志，2020，28（1）：185-190.
[7] International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies，multiple myeloma and related disorders：a report of the International Myeloma Working Group [J]. Br J Haematol，2003，121（5）：749-757.
[8] Greipp PR，San Miguel J，Durie BG，et al. International staging system for multiple myeloma [J]. J Clin Oncol，2005，23（25）：6281.
[9] 张之南.血液病诊断及疗效标准[M].北京：科学出版社，2007.
[10] Gratwohl A. The EBMT risk score [J]. Bone Marrow Transplant，2012，47（6）：749-756.
[11] 郁子馨.老年多发性骨髓瘤的临床表现及护理方法及效果[J].全科口腔医学电子杂志，2020，7（3）：81，86.
[12] 史欢欢，田晔，李斌，等.长链非编码RNA的作用机制[J].生命科学研究，2018，22（3）：229-234.
[13] 纪伟，吴洪坤，周琳.多发性骨髓瘤非编码RNA的研究进展[J].检验医学，2018，33（3）：264-268.
[14] 王海玲，李东霞.LncRNA与恶性肿瘤侵袭转移研究进展[J].现代肿瘤医学，2018，26（13）：2114-2117.
[15] 孙金旗，马佳康，任凯凯，等.TCGA数据库中肝癌相关差异长链非编码RNA筛选和功能预测[J].胃肠病学和肝病学杂志，2019，28（2）：147-153.
[16] 张晓丽，陈伟强，王烈峰.长链非编码RNA的功能与人类重大疾病的相关性[J].赣南医学院学报，2019，39（4）：410-416.
[17] 周传传.拷贝数变异相关长链非编码RNA对肝癌发生发展的影响及机制研究[D].上海：第二军医大学，2013.
[18] 范凡，冯继锋.长链非编码RNA在肿瘤耐药中的研究进展[J].现代肿瘤医学，2018，26（22）：176-181.
[19] Jariwala N，Sarkar D. Emerging role of lncRNA in cancer：a potential avenue in molecular medicine [J]. Ann Transl Med，2016，4（15）：286.
[20] Su P，Wang F，Qi B，et al. P53 Regulation-Association Long Non-Coding RNA （LncRNA PRAL） Inhibits Cell Proliferation by Regulation of P53 in Human Lung Cancer [J]. Med Sci Monit，2017，23（1）：1751-1758.
[21] Xiao G，Li Y，Wang Y，et al. LncRNA PRAL is closely related to clinical prognosis of multiple myeloma and the bortezomib sensitivity [J]. Exp Cell Res，2018，370（2）：254-263.
[22] Zuo C，Wang Z，Lu H，et al. Expression profiling of lncRNAs in C3H10T1/2 mesenchymal stem cells undergoing early osteoblast differentiation [J]. Mol Med Rep，2013，8（2）：463-467.
[23] Feo F，Simile MM，Pascale RM. Focal loss of long non-coding RNA-PRAL，as determinant of cell function and phenotype of hepatocellular carcinoma [J]. Ann Transl Med，2016，4（9）：183-189.
[24] Li D，Li H，Yang Y，et al. Long Noncoding RNA Urothelial Carcinoma-Associated 1 Promotes the Proliferation and Metastasis of Human Lung Tumor Cells by Regulating MicroRNA-144 [J]. Oncol Res，2018，26（4）：537-546.
[25] Zhu FF，Zheng FY，Wang HO，et al. Downregulation of lncRNA TUBA4B is Associated with Poor Prognosis for Epithelial Ovarian Cancer [J]. Pathol Oncol Res，2018， 24（2）：419-425.